We are testing NX-5948 in adults with relapsed or refractory B-cell malignancies. The goal is to see if this new treatment can help those who have not responded to other therapies.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed/Refractory B-cell Malignancies are types of cancers that affect B-cells in the immune system, which can return after treatment or resist initial therapies. This category includes various lymphomas and leukemias, often requiring specialized treatment approaches.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
